drugset / Trial / NCT07047365
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
Phase 3
Recruiting
416 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment
Summary
TQB2930 is a HER2 bispecific antibody drug. This study aims to evaluate the efficacy and safety of TQB2930 combined with investigator's choice of chemotherapy versus trastuzumab combined with investigator's choice of chemotherapy in subjects with HER2-positive advanced breast cancer who have received at least two prior lines of anti-HER2 therapy in the advanced station.
Timeline
- Start
- 2025-07-25
- Primary completion
- 2028-06
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB2930 | Unknown | 30 mg/kg | — |
| Comparator | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |
| Background | Capecitabine | Small molecule | — | — |
| Background | Eribulin | Small molecule | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Vinorelbine | Small molecule | — | — |